SUMMARY: Group B Streptococcus (GBS) is one of the leading causes of neonatal bacterial infections. Population-based surveillance of GBS-related invasive diseases among newborns and infants from 10 prefectures in Japan was performed between 2007 and 2012. The characteristics of cases and isolated GBS are described in this study. The incidence rate of GBS-related invasive diseases was 0.13 per 1,000 live births. Analysis of GBS samples obtained from 60 invasive cases showed that the most frequent serotypes were III (48.3z), Ia (30.0z), and Ib (10.0z). All isolates were susceptible to penicillin G, ampicillin, cefotaxime, imipenem, and panipenem. However, 14, 2, and 7 isolates were resistant to erythromycin, clindamycin, and both erythromycin and clindamycin, respectively. Multilocus sequence typing revealed that GBS sequence type (ST) 23, ST17, and ST335 caused higher incidences of meningitis. These data show that serotypes III, Ia, and Ib together caused more than 80z of invasive infections in Japanese infants, and that GBS strains are still susceptible to b-lactam antibiotics.
INTRODUCTION

Streptococcus agalactiae (group B Streptococcus
[GBS]) infects mainly infants and causes pneumonia, sepsis, and meningitis (1) (2) (3) . Invasive neonatal GBS infections can be classified as either early-onset disease (EOD) that occurs within the first week of life, or lateonset disease (LOD) that develops after the first week of life (4) . EOD is often caused by maternal transmission of GBS to the neonate through the birth canal during labor (1) (2) (3) . On the other hand, the route of infection for many LOD cases remains unknown. After the adoption of new preventative measures (i.e., universal antenatal screening and intrapartum antibiotic prophylaxis for culture-positive and high-risk pregnant women) recommended by the Centers for Disease Control and Prevention (CDC) in the United States (4), a reduction in the incidence of EOD, but not LOD, was observed (4, 5) .
Until now, 10 GBS serotypes have been classified based on specific capsular polysaccharides (6, 7) . In Japan, serotypes VIII and VI have been mainly isolated from the vagina of pregnant/puerperal women (8) . However, a broad survey of GBS serotyping, which causes invasive neonatal infections, has never been performed in Japan; hence, important disease-associated serotypes have not been well established.
Population-based surveillance of invasive GBS diseases in children aged º 5 years was conducted in 10 prefectures (i.e., Hokkaido, Niigata, Fukushima, Chiba, Mie, Okayama, Kochi, Fukuoka, Kagoshima, and Okinawa) in Japan between 2007 and 2012 (9) . The clinical features of 60 invasive infection cases that occurred in 8 prefectures (i.e., Niigata, Fukushima, Chiba, Mie, Kochi, Fukuoka, Kagoshima, and Okinawa) were collected, and the results of serotyping, antimicrobial susceptibility, and multilocus sequence typing (MLST) analysis of these GBS isolates are reported here.
MATERIALS AND METHODS
Invasive GBS cases and bacterial isolates: Between July 2007 and December 2012, population-based surveillance efforts included collection of data on invasive 
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GBS from Invasive Infant Infections in Japan infections in children aged º 5 years who reside in the 10 prefectures in Japan. Invasive infections caused by GBS were confirmed by isolation of the pathogenic agent obtained from a body site that was originally sterile. Information regarding invasive infections and isolates from hospitals in the 10 prefectures was provided to the Department of Bacteriology I, National Institute of Infectious Diseases. EOD and LOD were classified according to the recommendations by the CDC (i.e., EOD was classified as infections occurring within the first week of life, and LOD was classified as infections occurring in infants aged À1 week) (4). The identity of isolated bacteria was confirmed again to be S. agalactiae using the API 20 Strep Kit (bioM áerieux, Marcy l'Etoile, France). Serotypes were determined using a latex agglutination test. All GBS strains were initially serotyped using the Group B Streptococci Typing Antisera``SEIKEN'' (Denka Seiken, Tokyo, Japan) that contains 9 types of specific antisera for GBS. For strains that were not serotyped, the Streptococcus ImmuLex Strep-B Kit (Statens Serum Institut, Copenhagen, Denmark) containing serotype IX antiserum was used. Antimicrobial susceptibility test: The antimicrobial susceptibility of GBS isolates to 7 antibiotics (i.e., penicillin G, ampicillin, cefotaxime, imipenem, panipenem, erythromycin, and clindamycin) was analyzed using dry plates (Eiken Chemistry, Tokyo, Japan) by the broth microdilution method described by the Clinical and Laboratory Standards Institute (10) . Antimicrobial susceptibility breakpoints were defined according to the Clinical and Laboratory Standards Institute criteria (10) . In addition, the presence of wellknown macrolide resistance genes ermA, ermB, mefA/E, and linB was investigated by polymerase chain reaction (PCR) (11, 12) .
MLST analysis: Genomic DNA of GBS was purified using the High Pure PCR template purification kit (Roche Diagnostics, Tokyo, Japan). MLST was performed using primers that were designed as previously described (13) , and both strands of amplicons were sequenced. The allelic numbers and sequence types (STs) of all isolates were determined by comparing their sequences with those in the S. agalactiae MLST database (http://pubmlst.org/sagalactiae/).
Statistical analyses: Statistical analyses were performed using the Fisher's exact test. Odds ratios (ORs) and 95z confidence intervals (CIs) were calculated to evaluate the ability of different STs of GBS to invade the neonatal central nervous system.
RESULTS
Clinical features and bacterial characteristics: During the investigation period, a total of 151 sporadic GBSrelated invasive diseases, including 90 meningitis cases (59.6z), occurred in the 10 prefectures. The annual incidence rates of GBS-related invasive diseases were 0.07, 0.13, 0.15, 0.12, 0.13, and 0.15 per 1,000 live births from 2007 to 2012, respectively. The average rate was 0.13 per 1,000 live births.
The characteristics of the 60 invasive infection cases and their isolated bacteria from 8 of the 10 prefectures are listed in Table 1 . All 60 cases were analyzed independently in an epidemiological survey. Fifteen cases (25.0z) and 45 cases (75.0z) were EOD and LOD, respectively. The exact date of infection in 2 cases was unclear; however, symptoms presented within the first week of life. Among these 60 cases, 38 (6 EOD and 32 LOD) were diagnosed as meningitis, and 22 as bacteremia/sepsis. Two cases also presented with symptoms of pneumonia.
A total of 85 isolates were obtained from the blood and/or cerebrospinal fluid of 60 patients. All isolates were confirmed to be S. agalactiae. In 23 cases, more than 1 strain was isolated from different specimens. GBS isolated from the same patient showed identical serotypes and STs and similar antimicrobial susceptibility profiles (data not shown); therefore, it was considered as a single strain.
Serotype distribution of GBS isolates: Serotypes of 60 GBS isolates were determined using an agglutination kit. As shown in Table 1 , the most frequently identified GBS isolates from 15 EOD patients included serotypes III (5 cases; 33.3z) and Ia (4 cases; 26.7z). One case (6.7z) each of the serotypes Ib, II, IV, V, VI, and VIII was also identified among EOD patients. Among 45 LOD cases, serotype III was most frequently observed (24 cases; 53.3z), other serotypes identified were Ia (14 cases; 31.1z), Ib (5 cases; 11.1z), II (1 case; 2.2z), and IV (1 case; 2.2z). When EOD and LOD isolates were analyzed together, the most frequently observed serotypes were III (29 cases; 48.3z), Ia (18 cases; 30.0z), and Ib (6 cases; 10.0z). Furthermore, 2 cases (3.3z) each of GBS serotypes II and IV and 1 case (1.7z) each of serotypes V, VI, and VIII were detected. No cases of serotypes VII or IX were found among 60 analyzed cases. Overall, we found no obvious difference in serotype distribution between the different prefectures and isolated years (data not shown). The association between serotypes and the ability to invade the neonatal central nervous system was analyzed, but high invasive activity related to meningitis was not shown by any serotype (Fig. 1) .
Antimicrobial susceptibility of GBS isolates: All GBS isolates were susceptible to the b-lactam antibiotics used in this study (i.e., penicillin G, ampicillin, cefotaxime, imipenem, and panipenem) (data not shown). b-lactams (5) 
359
GBS from Invasive Infant Infections in Japan remain the first-line agents for treatment of GBS infections. Fourteen (23.3z), 2 (3.3z), and 7 (11.7z) GBS isolates were resistant to erythromycin, clindamycin, and both erythromycin and clindamycin, respectively ( Table 1 ). The remaining 37 (61.7z) GBS isolates were susceptible to both erythromycin and clindamycin.
Macrolide resistance in GBS is typically caused by the genes ermA, ermB, mefA/E, and linB (11, 12) . The presence of these genes was investigated (Table 1) , and no resistance-related genes were detected in 37 macrolide-sensitive GBS isolates, as expected. Among 14 erythromycin-resistant GBS isolates, ermA was detected in 10 (minimum inhibitory concentration [MIC] ＝ 1-2 mg/mL) and mefA/E in 4 (MIC AE 2 mg/mL). Neither ermB nor linB was detected in these 14 isolates. In the clindamycin-resistant GBS isolate, KSP401 (MIC AE 4 mg/mL), linB was detected. Among 7 GBS isolates with resistance to both erythromycin and clindamycin, ermB was detected in 6 and mefA/E in 1 isolate (Table  1) . However, none of the 4 resistance-related genes were identified in KSP652 (MIC of erythromycin, AE 4 mg/mL) or KSP76 (MIC of clindamycin, 2 mg/mL).
MLST profiles of GBS isolates from invasive infection cases: A total of 18 STs were observed by MLST analysis of 60 GBS isolates, including the following 5 new STs: ST571, ST572, ST574, ST575, and ST654 (Tables 1 and 2 ). Although several STs were found, all 18 GBS serotype Ia isolates belonged to clonal complex (CC) 23, whereas 6 GBS serotype Ib isolates belonged to CC10. GBS serotype III isolates were divided into the following 2 CC groups: CC17 (9 isolates; 31.0z) and CC19 (20 isolates; 69.0z) ( Table 2 ). Among 20 GBS serotype III isolates that caused meningitis, 6 (66.7z) and 14 (70.0z) belonged to CC17 and CC19, respectively ( Table 1 ). The incidence of meningitis was not different between CC17 and CC19 (OR ＝ 0.95; 95z CI ＝ 0.28-3.29). STs of other GBS serotypes are summarized in Table 2 . Among the cases caused by the 3 most common STs (i.e., ST23, ST17, and ST335), meningitis was detected in 11/16 (68.8z), 5/8 (62.5z), and 9/12 (75.0z) cases, respectively. The total incidence rate of meningitis caused by all 3 STs was 69.4z, whereas the incidence rate of meningitis caused by other STs was 54.2z (13/24) . Although no significant difference (OR ＝ 1.92; 95z CI ＝ 0.66-5.61) was observed, the GBS isolates ST23, ST17, and ST335 caused meningitis at higher incidence rates compared with those for other isolates.
DISCUSSION
In the present study, we analyzed the characteristics of invasive GBS infections in 60 Japanese infants as part of a population-based study in 10 prefectures in Japan that were chosen without geographic bias. Results obtained from these 60 cases are considered to represent the current epidemiology of GBS-related invasive neonatal infections in Japan.
The serotype analysis of GBS indicated that the most common serotype was III, followed by serotypes Ia and Ib; these results are similar to those for the serotype distribution of GBS that caused invasive infections in other countries (12, 14, 15) . However, we uncovered the 2 following unique features among GBS-related infections in our study: (i) the high incidence rate of meningitis (59.6z) and (ii) the low incidence rate (1.7z) of serotype V GBS-related infections. A previous surveillance study conducted between 2004 and 2010 in Japan evaluated 250 GBS-related invasive infections in 152 hospitals. The investigators of this study showed that the incidence rates of EOD and LOD were 0.08 and 0.10 per 1,000 live births, respectively, and only approximately one-third of all cases had meningitis (16) . The reasons for the high incidence rates of GBS infection (0.13/1,000 live births) and meningitis (59.6z) in the 10 prefectures remain unknown. In addition, only 1 case of EOD caused by serotype V was found among all cases in the present study; however, serotype V was the third most commonly isolated serotype among patients with GBS invasive diseases in England, Wales, and the United States (14, 15) .
In several regions and countries, the CC17 GBS strain has been shown to have an increased ability to invade the neonatal central nervous systems and cause meningitis (17) (18) (19) (20) (21) (22) . However, we did not find a high incidence of meningitis caused by the CC17 GBS strain in the present study. Although the reason remains unknown, the GBS isolates ST23, ST17, and ST335 seem to be involved in the development of meningitis. The small sample size is a limitation of our study and may have contributed to our statistical findings. Recently, Morozumi et al. reported that GBS ST335 containing the mefA/E gene gradually increased the frequency of invasive GBS infections in Japanese infants between 2006 and 2011 (23) . GBS ST335 was also isolated at a high rate in our investigation (20.0z; 12/60 cases). However, most of the ST335 strains (10/12) possessed the ermA gene, whereas only 1 strain possessed the mefA/E gene ( Table  1) . Although it remains unclear, differences in the isolation region may have contributed to the variation in the ST335 strain.
Of 60 investigated cases, the number of LOD cases was almost 2-fold greater than that of EOD cases. The source of infection and pathways of most LODs still remain unknown, and no effective means for disease prevention are available. Therefore, vaccination may be the best preventive measure against not only LOD but also EOD GBS infections. Epidemiological studies of capsular polysaccharide-protein conjugate vaccines for prevention of GBS infections in infants have been conducted since the 1990s (24) . The development of a trivalent polysaccharide-protein conjugate vaccine, which includes Ia, Ib, and III serotype polysaccharides, has advanced to a phase II clinical trial, and phase III of this study is currently being planned (25) . In the present surveillance study, serotype analysis revealed that GBS serotypes Ia, Ib, and III caused 88.3z of 60 invasive cases. Therefore, the trivalent polysaccharide-protein conjugate vaccine could have theoretically prevented most cases of GBS-related invasive disease among Japanese infants. Hence, we highly recommend the early licensing of GBS vaccines. Ongoing monitoring of the incidence and distribution of serotypes for disease surveillance is important to determine the serotype components that would be most beneficial for inclusion in a GBS conjugate vaccine. Furthermore, ongoing monitoring will enable the continued evaluation of these preventive measures after the distribution of the vaccine. Further population-based surveillance studies of bacterial invasive infections in Japanese children are required.
